(The 9th China International Import Expo) Global debut, Asian debut, and CIIE first exhibition. See the sources of innovation at the China International Import Expo.

China News Service, Shanghai, November 7 (Reporter Chen Jing) At the 9th China International Import Expo held in Shanghai on the 6th, the first exhibitions, launches, and debuts of a series of innovative products and companies attracted a lot of attention, and the distance between global innovation and Chinese clinical practice was shortened to the shortest.

At Eli Lilly's booth, Eli Lilly's world's first and currently only oral small molecule GLP-1 drug, the oral small molecule GLP-1 receptor agonist orforglipron, made its debut at the CIIE. It is reported that the drug can be taken once a day and is not restricted by food and water. Currently, Eli Lilly has submitted its marketing application to the National Medical Products Administration for weight management and type 2 diabetes.

Eight global phase III clinical studies of orflugliflozin conducted by Lilly for obesity and type 2 diabetes have achieved positive results. Relevant studies have enrolled more than 10,000 patients, of which 6 studies have Chinese patients participating.

On that day, Zeiss made its world premiere of a new generation of aspheric intraocular lens - PT LUNANA™ posterior chamber phakic intraocular lens (hereinafter referred to as "PT LUNANA"). It is reported that this innovative product fully integrates Zeiss' cutting-edge optical technology with local R&D and manufacturing capabilities. It was developed by Wuxi Carl Zeiss Leiming Vision Medical Technology Co., Ltd., a joint venture company of Zeiss in China, and will soon be produced locally. This innovative product has three major innovative advantages, including: new generation aspheric optical design, innovative flexible materials and refined crystal size and power selection.

"China is not only the largest single market in the world for Zeiss, but also an important source of innovation for us." said Martin Fischer, President and CEO of Zeiss Greater China. "PT LUNANA is an innovative result that we have taken root in China and jointly incubated with local partners. It confirms Zeiss's development philosophy of 'in China, for the world' and hopes to broaden the choices of doctors and patients and contribute to the high-quality development of refractive diagnosis and treatment in China."

Qian Ying, head of ophthalmic endoscopy at Zeiss China Medical Department, revealed that in the future, Zeiss will also introduce an intelligent analysis platform to improve the predictability of myopia correction and allow more myopia patients to benefit from it.

Sonova Group made its second appearance at the CIIE this year. At its booth, reporters saw that the Phonak Kunlun (EON) AI hearing aid exhibited for the first time in Asia is equipped with relevant AI chips. By identifying and separating speech and background noise, it helps users cope with complex listening environments such as dinner parties and multi-person conversations, and takes into account Chinese listening, outdoor wind noise and mobile phone connection needs. The AB INTEGRO CI AI sound processor, which is exhibited for the first time in the world, can focus on demonstrating sound direction recognition and speech processing in noisy environments.

At the CIIE venue, reporters learned that Johnson & Johnson Medical Technology’s ETHICON™ 4000 45mm preset chip 3D three-dimensional nail-forming laparoscopic stapler made its Asian debut.

According to reports, as minimally invasive surgery continues to develop toward sophistication, especially in complex surgical scenarios such as thoracic surgery, the anatomy of key structures such as blood vessels and bronchi in lung lobes and lung segments is complex, and surgeons need to operate in a narrow chest space and a restricted surgical field. At the same time, the lungs are rich in blood vessels. Once bleeding occurs during surgery, it may increase the difficulty for doctors to stop bleeding and subsequent operations, and increase the complexity of surgical operations. These challenges place higher requirements on the operational flexibility, precision and stability of tissue closure of anastomotic devices.

The above-mentioned stapler is the first to be equipped with core 3D technology and adjustable olecranon, which is a milestone in the development of endoscopic staplers. Multiple innovations work together to better meet the disconnection and integration needs of complex surgical fields and challenging organizations. "The CIIE is not only an important window for displaying global innovation achievements, but also provides an important platform for accelerating innovation to clinical practice," said Ou Liwen, general manager of the Surgical Division of Johnson & Johnson Medical Technology China. In 2025, the ETHICON™ 4000 60mm stapler made its Asian debut at the 8th CIIE, and subsequently accelerated its move toward clinical practice.

Shanghai Zedman Pharmaceutical Technology Co., Ltd. (hereinafter referred to as: Zedman Pharmaceutical) made its debut as a member of the "Zhangjiang Incubation Exhibition Group", focusing on the latest achievements of aryl hydrocarbon receptor (AhR) technology from basic research, drug development to industrial application. Dr. Chen Genghui, chairman of Zedman Pharmaceuticals, told reporters: "For Zedman Pharmaceuticals, the CIIE is not only a window to display innovative results, but also an important opportunity for global partners to understand China's original technology and the AhR track."

It is reported that more than 30 AhR target-related clinical studies have been carried out simultaneously in more than ten countries around the world. Research related to AhR targets is moving from "no man's land" to simultaneous exploration in multiple disease fields. According to reports, Zeidman has currently deployed 15 R&D pipelines around AhR, covering skin, digestion, ophthalmology and other directions; among them, TAN-118, an oral AhR agonist for inflammatory bowel disease, has been clinically licensed in China and the United States and has been advanced to Phase II.

In the future, Zeideman will continue to use the CIIE as a connecting point to deepen domestic and foreign research, clinical and industrial cooperation, and promote the platformization, industrialization and globalization of AhR technology while expanding the pipeline.